Millipore Sigma Vibrant Logo

435801 Licofelone, Potassium Salt, Monohydrate - CAS 156897-06-2 - Calbiochem

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: FLAP Inhibitor II, mPGES-1 Inhibitor II, 2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V

435801
Preis & Verfügbarkeit

Übersicht

Replacement Information

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
435801-25MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Glasflasche 25 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA cell-permeable, orally active arylpyrrolizine carboxylate that is structurally and pharmacologically similar to, but less potent than, MK-886 (Cat. No. 475889). Effectively suppresses cellular Cox pathway PGE2 production by inhibiting COX-1 and mPGES-1, but not COX-2 (IC50 = 0.8, 6, and >30 µM, respectively), and inhibits cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation (IC50 = 0.18 to 3.6 µM against ionophore-stimulated LB4 production from bovine and human PMNL, respectively) by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity. Unlike NSAIDs that target only COX pathway, Licofelone does not cause gastrointestinal damages when applied in vivo.
      Catalogue Number435801
      Brand Family Calbiochem®
      SynonymsFLAP Inhibitor II, mPGES-1 Inhibitor II, 2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V
      References
      ReferencesLaufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
      Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
      Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
      Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
      Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
      Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
      Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
      Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
      Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
      Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.
      Product Information
      CAS number156897-06-2
      FormWhite powder
      Hill FormulaC₂₃H₂₁ClKNO₂•H₂O
      Chemical formulaC₂₃H₂₁ClKNO₂•H₂O
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Target5-LOX
      Primary Target IC<sub>50</sub>0.21 µ
      Secondary targetCOX
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsUnstable in solution. Reconstitute just prior to use.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      435801-25MG 04055977210323

      Documentation

      Literatur

      Übersicht
      Laufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
      Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
      Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
      Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
      Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
      Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
      Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
      Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
      Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
      Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-June-2013 JSW
      SynonymsFLAP Inhibitor II, mPGES-1 Inhibitor II, 2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid, ML3000, ML-3000, COX-1 Inhibitor V
      DescriptionA cell-permeable, orally active arylpyrrolizine carboxylate that is both structurally and pharmacologically similar to, but less potent than, MK-886 (Cat. No. 475889). Both MK-886 and Licofelone effectively suppress cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2 (IC50 = 0.8, 6, and >30 µM, respectively, by Licofelone), and both compounds suppress cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation (IC50 = 0.18 to 3.6 µM against ionophore-stimulated bovine and human PMNL LB4 production by Licofelone) by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (No inhibition up to 10 µM Licofelone). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, Licofelone does not cause gastrointestinal damages when applied in vivo.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number156897-06-2
      Chemical formulaC₂₃H₂₁ClKNO₂•H₂O
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsUnstable in solution. Reconstitute just prior to use.
      Toxicity Standard Handling
      ReferencesLaufer, S. A., et al. 1994. Arzneimittelforschung. 44, 629.
      Laufer, S., et al. 1994. Arzneimittelforschung. 45, 27.
      Wallace, J. L., et al. 1994. Eur J Pharmacol. 271, 525.
      Alvaro-Garcia, J. M., et al. 2004. Rheumatology. 43 Supple1, i21.
      Koeberle, A., et al. 2008. J Pharmacol Exp Ther. 326, 975.
      Fischer, L., et al. 2007. Br J Pharmacol. 152, 471.
      Laufer, S. A., et al. 1994. J Med Chem. 37, 1894.
      Vidal, C., et al. 2007. J Pharmacol Exp Ther. 320, 108.
      Liedtke, A. J., et al. 2009. J Med Chem. 52, 4968.
      Bias, P., et al. 2004. Am J Gastroenterol. 99, 611.